nach oben

International Urology and Nephrology

Erschienen in:

28.11.2022 | Nephrology - Original Paper

Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial

verfasst von: Wutipong Triwatana, Bancha Satirapoj, Ouppatham Supasyndh, Naowanit Nata

Erschienen in: International Urology and Nephrology | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Aim

Elevated fibroblast growth factor-23 (FGF23) is an established marker of cardiovascular disease among patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD). Recently, circulating FGF23 positively correlated with insulin resistance level among patients with CKD. Pioglitazone improves insulin sensitivity and it may have potential for treating CKD-related FGF23 overactivity.

Methods

A randomized, open-label, controlled trial was performed among patients with T2DM and CKD. Eligible participants were randomly assigned to either oral 15 mg/day of pioglitazone (N = 22) or control group (N = 24) for 16 weeks. Serum FGF23 and homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were measured.

Results

Forty-six patients completed the trial. After 16 weeks of treatment, significant decreases in serum intact FGF23 level (median change − 49.01 (IQR, − 103.51 to − 24.53) vs. 1.07 (IQR, − 22.4–39.53) pg/mL, P = 0.01) and HOMA-IR (mean change − 1.41 (95% CI, − 2.24 to − 0.57) vs. − 0.05 (95% CI, − 1.00–0.89), P = 0.031) were observed in the pioglitazone group compared with the control group. HemoglobinA1C also significantly decreased in the pioglitazone group compared with the control group. No difference was found in the changes of serum phosphorus, calcium and serum intact parathyroid hormone between the two groups. Changes of FGF23 were positively associated with changes of HOMA-IR (R = 0.47) and insulin levels (R = 0.47). No serious adverse event was reported during the study.

Conclusion

This study confirmed that pioglitazone effectively reduced serum FGF23 levels and related to improved insulin sensitivity among patients with T2DM and CKD.

Clinical trial registration

TCTR20210316009.

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121(11):4393–4408. https://doi.org/10.1172/JCI46122CrossRefPubMedPubMedCentral

Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M (2011) Chronic renal insufficiency cohort study G fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305(23):2432–2439. https://doi.org/10.1001/jama.2011.826CrossRefPubMedPubMedCentral

Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, Bazzano LA, Xie D, Kretzler M, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, Wolf M, Chronic Renal Insufficiency C (2012) Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 7(7):1155–1162. https://doi.org/10.2215/CJN.13281211CrossRefPubMedPubMedCentral

Marchelek-Mysliwiec M, Dziedziejko V, Dolegowka K, Pawlik A, Safranow K, Stepniewska J, Wisniewska M, Malyszko J, Ciechanowski K (2020) Association of FGF19, FGF21 and FGF23 with carbohydrate metabolism parameters and insulin resistance in patients with chronic kidney disease. J Appl Biomed 18(2–3):61–69. https://doi.org/10.32725/jab.2020.005CrossRefPubMed

Garland JS, Holden RM, Ross R, Adams MA, Nolan RL, Hopman WM, Morton AR (2014) Insulin resistance is associated with Fibroblast Growth Factor-23 in stage 3–5 chronic kidney disease patients. J Diabetes Complicat 28(1):61–65. https://doi.org/10.1016/j.jdiacomp.2013.09.004CrossRef

Fayed A, El Nokeety MM, Heikal AA, Abdulazim DO, Naguib MM, Sharaf El Din UAA, Vascular Calcification G (2018) Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients. Ren Fail 40(1):226–230. https://doi.org/10.1080/0886022X.2018.1455594CrossRefPubMedPubMedCentral

Bar L, Feger M, Fajol A, Klotz LO, Zeng S, Lang F, Hocher B, Foller M (2018) Insulin suppresses the production of fibroblast growth factor 23 (FGF23). Proc Natl Acad Sci U S A 115(22):5804–5809. https://doi.org/10.1073/pnas.1800160115CrossRefPubMedPubMedCentral

Diamant M, Heine RJ (2003) Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 63(13):1373–1405CrossRefPubMed

Derosa G, Maffioli P (2012) Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 5(2):272–281. https://doi.org/10.2174/1874467211205020272CrossRefPubMed

10.

Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J, Xie H, Wahl P, Schiavenato E, Dosch A, Gutierrez OM, Diego J, Lenz O, Contreras G, Mendez A, Weiner RB, Wolf M (2013) Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol 8(6):1009–1018. https://doi.org/10.2215/CJN.09250912CrossRefPubMedPubMedCentral

11.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419. https://doi.org/10.1007/BF00280883CrossRefPubMed

12.

Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, Czaja MJ, Bartz R, Abraham R, Di Marco GS, Brand M, Wolf M, Faul C (2016) Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 90(5):985–996. https://doi.org/10.1016/j.kint.2016.05.019CrossRefPubMedPubMedCentral

13.

Defronzo RA, Mehta RJ (1995) Schnure JJ (2013) Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract 41(2):132–147. https://doi.org/10.3810/hp.2013.04.1062CrossRef

14.

Esterson YB, Zhang K, Koppaka S, Kehlenbrink S, Kishore P, Raghavan P, Maginley SR, Carey M, Hawkins M (2013) Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients. J Investig Med 61(8):1152–1160. https://doi.org/10.2310/JIM.0000000000000017CrossRefPubMedPubMedCentral

15.

Zaheer S, de Boer IH, Allison M, Brown JM, Psaty BM, Robinson-Cohen C, Michos ED, Ix JH, Kestenbaum B, Siscovick D, Vaidya A (2017) Fibroblast growth factor 23, mineral metabolism, and adiposity in normal kidney function. J Clin Endocrinol Metab 102(4):1387–1395. https://doi.org/10.1210/jc.2016-3563CrossRefPubMedPubMedCentral

16.

Mirza MA, Alsio J, Hammarstedt A, Erben RG, Michaelsson K, Tivesten A, Marsell R, Orwoll E, Karlsson MK, Ljunggren O, Mellstrom D, Lind L, Ohlsson C, Larsson TE (2011) Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 31(1):219–227. https://doi.org/10.1161/ATVBAHA.110.214619CrossRefPubMed

17.

Wahl P, Xie H, Scialla J, Anderson CA, Bellovich K, Brecklin C, Chen J, Feldman H, Gutierrez OM, Lash J, Leonard MB, Negrea L, Rosas SE, Anderson AH, Townsend RR, Wolf M, Isakova T (2012) Chronic Renal Insufficiency Cohort Study G Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. Diabetes Care 35(5):994–1001. https://doi.org/10.2337/dc11-2235CrossRefPubMedPubMedCentral

18.

Lee JE, Gohda T, Walker WH, Skupien J, Smiles AM, Holak RR, Jeong J, McDonnell KP, Krolewski AS, Niewczas MA (2013) Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1. PLoS ONE 8(3):e58007. https://doi.org/10.1371/journal.pone.0058007CrossRefPubMedPubMedCentral

19.

Schoppet M, Hofbauer LC, Brinskelle-Schmal N, Varennes A, Goudable J, Richard M, Hawa G, Chapurlat R, Szulc P (2012) Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab 97(4):E575-583. https://doi.org/10.1210/jc.2011-2836CrossRefPubMed

20.

Donate-Correa J, Martin-Nunez E, Gonzalez-Luis A, Ferri CM, Luis-Rodriguez D, Tagua VG, Mora-Fernandez C, Navarro-Gonzalez JF (2021) Pathophysiological implications of imbalances in fibroblast growth factor 23 in the development of diabetes. J Clin Med 10(12):2583. https://doi.org/10.3390/jcm10122583CrossRefPubMedPubMedCentral

21.

Wojcik M, Janus D, Dolezal-Oltarzewska K, Drozdz D, Sztefko K, Starzyk JB (2012) The association of FGF23 levels in obese adolescents with insulin sensitivity. J Pediatr Endocrinol Metab 25(7–8):687–690. https://doi.org/10.1515/jpem-2012-0064CrossRefPubMed

22.

Wojcik M, Dolezal-Oltarzewska K, Janus D, Drozdz D, Sztefko K, Starzyk JB (2012) FGF23 contributes to insulin sensitivity in obese adolescents—preliminary results. Clin Endocrinol (Oxf) 77(4):537–540. https://doi.org/10.1111/j.1365-2265.2011.04299.xCrossRefPubMed

23.

Rodriguez A, Catalan V, Gomez-Ambrosi J, Fruhbeck G (2011) Aquaglyceroporins serve as metabolic gateways in adiposity and insulin resistance control. Cell Cycle 10(10):1548–1556. https://doi.org/10.4161/cc.10.10.15672CrossRefPubMedPubMedCentral

24.

Adeva-Andany MM, Martinez-Rodriguez J, Gonzalez-Lucan M, Fernandez-Fernandez C, Castro-Quintela E (2019) Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metab Syndr 13(2):1449–1455. https://doi.org/10.1016/j.dsx.2019.02.023CrossRefPubMed

25.

Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B (2017) Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open 7(1):e013927. https://doi.org/10.1136/bmjopen-2016-013927CrossRefPubMedPubMedCentral

26.

Spence JD, Viscoli C, Kernan WN, Young LH, Furie K, DeFronzo R, Abdul-Ghani M, Dandona P, Inzucchi SE (2022) Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. Diabetes Obes Metab 24(6):1150–1158. https://doi.org/10.1111/dom.14687CrossRefPubMed

Titel: Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial
verfasst von: Wutipong Triwatana
Bancha Satirapoj
Ouppatham Supasyndh
Naowanit Nata
Publikationsdatum: 28.11.2022
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 5/2023
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-022-03420-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial

Abstract